Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer

癌症研究 CXCL2型 肿瘤微环境 趋化因子受体 CXCL5型 趋化因子受体 CXCL10型 趋化因子 CXCL14型 C-C趋化因子受体6型 20立方厘米 CCL5 CCL21型 CXCL9型 CXCL1型 CXCL16型 CCL7型 生物 免疫学 免疫系统 T细胞 白细胞介素2受体 肿瘤细胞
作者
Na Song,Kai Cui,Liqun Zeng,Mengxiao Li,Yanwu Fan,Pingyu Shi,Ziwei Wang,Wei Su,Haijun Wang
出处
期刊:European Journal of Pharmacology [Elsevier BV]
卷期号:967: 176357-176357 被引量:41
标识
DOI:10.1016/j.ejphar.2024.176357
摘要

The chemokines/chemokine receptors pathway significantly influences cell migration, particularly in recruiting immune cells to the tumor microenvironment (TME), impacting tumor progression and treatment outcomes. Emerging research emphasizes the involvement of chemokines in drug resistance across various tumor therapies, including immunotherapy, chemotherapy, and targeted therapy. This review focuses on the role of chemokines/chemokine receptors in pancreatic cancer (PC) development, highlighting their impact on TME remodeling, immunotherapy, and relevant signaling pathways. The unique immunosuppressive microenvironment formed by the interaction of tumor cells, stromal cells and immune cells plays an important role in the tumor proliferation, invasion, migration and therapeutic resistance. Chemokines/chemokine receptors, such as chemokine ligand (CCL) 2, CCL3, CCL5, CCL20, CCL21, C-X-C motif chemokine ligand (CXCL) 1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL17, and C-X3-C motif chemokine ligand (CX3CL)1, derived mainly from leukocyte cells, cancer-related fibroblasts (CAFs), pancreatic stellate cells (PSCs), and tumor-associated macrophages (TAMs), contribute to PC progression and treatment resistance. Chemokines recruit myeloid-derived suppressor cells (MDSC), regulatory T cells (Tregs), and M2 macrophages, inhibiting the anti-tumor activity of immune cells. Simultaneously, they enhance pathways like epithelial-mesenchymal transition (EMT), Akt serine/threonine kinase (AKT), extracellular regulated protein kinases (ERK) 1/2, and nuclear factor kappa-B (NF-κB), etc., elevating the risk of PC metastasis and compromising the efficacy of radiotherapy, chemotherapy, and anti-PD-1/PD-L1 immunotherapy. Notably, the CCLx-CCR2 and CXCLx-CXCR2/4 axis emerge as potential therapeutic targets in PC. This review integrates recent findings on chemokines and receptors in PC treatment, offering valuable insights for innovative therapeutic approaches.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
美丽的依琴完成签到,获得积分10
刚刚
刚刚
HEQ发布了新的文献求助10
1秒前
1秒前
EvanGao发布了新的文献求助20
1秒前
1秒前
可靠的焦完成签到,获得积分10
2秒前
fhw完成签到 ,获得积分10
4秒前
4秒前
爆爆完成签到,获得积分10
5秒前
ddz发布了新的文献求助10
6秒前
detail完成签到 ,获得积分10
6秒前
7秒前
白白不是球完成签到,获得积分10
7秒前
田様的应助被hwx采纳,获得10
7秒前
lili完成签到,获得积分10
8秒前
小巧的草莓完成签到,获得积分10
9秒前
9秒前
靓丽夜蕾发布了新的文献求助10
9秒前
9秒前
爆米花的应助被tan2026采纳,获得10
9秒前
nono完成签到,获得积分10
10秒前
11秒前
现代风格发布了新的文献求助10
12秒前
qqllyy完成签到,获得积分10
12秒前
orixero的应助被勤恳的亦瑶采纳,获得10
12秒前
阿智发布了新的文献求助10
13秒前
13秒前
帕尼尼同学的应助被车厘子采纳,获得10
13秒前
hainao发布了新的文献求助10
15秒前
Firsterchao发布了新的文献求助10
16秒前
王猛完成签到,获得积分10
17秒前
mengzhao完成签到,获得积分10
17秒前
汉堡包的应助被chang采纳,获得10
18秒前
向中恶发布了新的文献求助10
18秒前
史永桂完成签到,获得积分10
18秒前
Sadie发布了新的文献求助10
18秒前
谁跟你嘻嘻哈哈完成签到,获得积分10
19秒前
19秒前
嘻嘻哈哈的应助被幽默的山柏采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Aspects of Post-SPE Phonology 2000
Recombinant human Type III collagen with native-like assembly and real biomaterial performance 1000
Children in Mind: Their mental health in today’s world and what we can do to help them 900
Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals 888
Rosenblum, Global Change Biology 800
Holistic Discourse Analysis, Second Edition by Robert E. Longacre (2012-09-10) 666
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 物理 有机化学 化学工程 内科学 生物化学 复合材料 催化作用 心理学 细胞生物学 无机化学 电极 光电子学 人工智能
热门帖子
关注 科研通微信公众号,转发送积分 7874550
求助须知:如何正确求助?哪些是违规求助? 9390226
关于积分的说明 20781244
捐赠科研通 7475984
什么是DOI,文献DOI怎么找? 3352235
关于科研通互助平台的介绍 2492858
邀请新用户注册赠送积分活动 2379035